Curant Rare and Cencora Form Strategic Partnership to Streamline Rare Disease Therapy Commercialization
核心洞察
Curant Rare (搜索) and Cencora announced a strategic collaboration to provide pharmaceutical companies with integrated solutions for commercializing rare disease (搜索) therapies.
The partnership combines Cencora's pharmaceutical logistics and commercialization solutions with Curant Rare (搜索)'s specialty pharmacy services to address unique challenges in rare disease (搜索) therapy access.
The collaboration aims to streamline commercialization pathways, optimize patient journeys, and expedite speed-to-therapy for rare and orphan drug (搜索) products.
Curant Rare (搜索) and Cencora have announced a strategic collaboration designed to address the complex commercialization challenges facing rare disease (搜索) therapies. The partnership, announced on January 22, 2026, aims to provide pharmaceutical companies developing rare disease treatments with an integrated solution that combines both organizations' specialized capabilities.
Addressing Unique Commercialization Challenges
Rare disease (搜索) therapies face distinctive obstacles in reaching patients, including complex regulatory pathways and significant access barriers. The collaboration leverages Cencora's pharmaceutical logistics services and commercialization solutions, including pharmacovigilance and market access support, alongside Curant Rare (搜索)'s specialty pharmacy services and omnichannel patient engagement solutions.
The integrated approach is designed to streamline the path to commercialization, helping pharmaceutical companies bring therapies to market more efficiently while optimizing the patient journey and expediting speed-to-therapy.
"Our combined efforts focus on overcoming challenges in access and implementation," said Patrick Dunham, CEO and Co-Founder of Curant Health (搜索). "The goal of this collaboration is to transform the way Rare and Orphan therapies are introduced to market, ensuring they reach the patients who need them most."
Enhanced Patient Experience Tools
Through this partnership, pharmaceutical companies will gain access to advanced tools specifically designed to improve patient experiences. These include actionable insights into real-world evidence and patient-reported outcomes, providing companies with valuable data to optimize their therapeutic approaches.
Specialized Expertise in Rare Disease Care
Curant Rare (搜索) brings over 25 years of experience in rare disease (搜索) patient care, operating as a specialized business unit of Curant Health (搜索). The organization provides bespoke specialty pharmacy and Real-World Evidence solutions focused on rare and ultra-rare patient populations. Their approach emphasizes comprehensive high-quality care while prioritizing patients' physical and psychosocial well-being through validated Medication Care Management® services.
The company has established a proven track record in achieving best-in-class patient adherence and Quality of Life outcomes, positioning it as a valuable partner for pharmaceutical companies seeking to navigate the complexities of rare disease (搜索) therapy commercialization.
This collaboration represents a significant step toward addressing the systemic challenges that have historically impeded access to rare disease (搜索) treatments, potentially benefiting both pharmaceutical companies and the patients they serve.